These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16126403)

  • 21. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
    Koster A; Kukucka M; Bach F; Meyer O; Fischer T; Mertzlufft F; Loebe M; Hetzer R; Kuppe H
    Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tirofiban-associated acute thrombocytopenia.
    Tuhta AG; Yeşildağ O; Köprülü D
    Acta Cardiol; 2006 Oct; 61(5):577-9. PubMed ID: 17117761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease.
    Azar RR; Badaoui G; Sarkis A; Kassab R; Salamé E; Klaymé S; Naman R; Germanos M
    Am J Cardiol; 2005 Jan; 95(2):236-40. PubMed ID: 15642557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery.
    Genoni M; Zeller D; Bertel O; Maloigne M; Turina M
    J Thorac Cardiovasc Surg; 2001 Sep; 122(3):630-2. PubMed ID: 11547328
    [No Abstract]   [Full Text] [Related]  

  • 26. Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention.
    Siotia A; Buckland R; Judge HM; Sastry P; Storey RF
    Thromb Haemost; 2006 Jun; 95(6):997-1002. PubMed ID: 16732379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of coronary prestenting platelet inhibition on coronary poststenting inflammation.
    Sacristán D; López-Farré AJ; Zamorano-León JJ; Azcona L; Fernández-Ortiz A; Romero J; Farré J; Macaya C
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):286-92. PubMed ID: 18356694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Profound thrombocytopenia associated with tirofiban: case report and review of literature.
    Patel S; Patel M; Din I; Reddy CV; Kassotis J
    Angiology; 2005; 56(3):351-5. PubMed ID: 15889207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
    Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
    Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban.
    Stepinska J; Banaszewski M; Konopka A; Szajewski T
    Thromb Haemost; 2002 Feb; 87(2):355-6. PubMed ID: 11858506
    [No Abstract]   [Full Text] [Related]  

  • 31. Tirofiban blocks platelet adhesion to fibrin with minimal perturbation of GpIIb/IIIa structure.
    Hantgan RR; Stahle MC; Jerome WG; Nagaswami C; Weisel JW
    Thromb Haemost; 2002 May; 87(5):910-7. PubMed ID: 12038797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now?
    Maree A; Fitzgerald DJ
    Semin Vasc Med; 2003 Nov; 3(4):385-90. PubMed ID: 15199445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.
    Januzzi JL; Snapinn SM; DiBattiste PM; Jang IK; Theroux P
    Circulation; 2002 May; 105(20):2361-6. PubMed ID: 12021221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events).
    Lim MJ; Eagle KA; Gore JM; Anderson FA; Dabbous OH; Mehta RH; Granger CB; Fox KA; Spencer FA; Goldberg RJ;
    Am J Cardiol; 2005 Oct; 96(7):917-21. PubMed ID: 16188516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of glycoprotein IIb/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stenting; a prospective, randomized study.
    Wong P; Harding S; Inglessis I; Choi CJ; Walters D; Chang Y; Gimelli G; Jang IK
    J Thromb Thrombolysis; 2003 Dec; 16(3):163-6. PubMed ID: 15087602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban].
    Galli M; Vassanelli C
    Ital Heart J Suppl; 2001 Oct; 2(10):1127-9. PubMed ID: 11723619
    [No Abstract]   [Full Text] [Related]  

  • 38. Selective inhibition of the platelet phosphoinositide 3-kinase p110beta as promising new strategy for platelet protection during extracorporeal circulation.
    Straub A; Wendel HP; Dietz K; Schiebold D; Peter K; Schoenwaelder SM; Ziemer G
    Thromb Haemost; 2008 Mar; 99(3):609-15. PubMed ID: 18327411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report.
    Demirkan B; Guray Y; Guray U; Korkmaz S
    J Thromb Thrombolysis; 2006 Aug; 22(1):77-8. PubMed ID: 16786237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.
    Tcheng JE
    Am Heart J; 2000 Feb; 139(2 Pt 2):S38-45. PubMed ID: 10650315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.